Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/31/2020 08/03/2020 08/04/2020 08/05/2020 08/06/2020 Date
80.24(c) 82.54(c) 81.67(c) 81.64(c) 81.05(c) Last
11 726 443 10 118 572 6 888 062 6 198 438 6 922 591 Volume
+1.58% +2.87% -1.05% -0.04% -0.72% Change
More quotes
Financials (USD)
Sales 2020 47 840 M - -
Net income 2020 12 197 M - -
Net Debt 2020 16 135 M - -
P/E ratio 2020 16,9x
Yield 2020 2,95%
Sales 2021 51 158 M - -
Net income 2021 13 118 M - -
Net Debt 2021 11 525 M - -
P/E ratio 2021 16,0x
Yield 2021 3,16%
Capitalization 205 B 205 B -
EV / Sales 2020 4,62x
EV / Sales 2021 4,23x
Nbr of Employees 71 000
Free-Float 70,5%
More Financials
Company
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (72.1%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of... 
Sector
Pharmaceuticals
Calendar
09/14Ex-dividend day for
More about the company
Surperformance© ratings of Merck & Co., Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK & CO., INC.
08/05MERCK : & CO., INC. Management's Discussion and Analysis of Financial Condition ..
AQ
08/05MERCK : Animal Health Completes Acquisition of IdentiGEN
BU
08/04MERCK : and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efino..
BU
08/03MERCK : Announces Second-Quarter 2020 Financial Results
AQ
08/03Gilead Shows the Dangers of Covid-19 Drug Mania -- Heard on the Street
DJ
08/03MERCK : Animal Health Completes Acquisition of Worldwide Rights to VECOXAN® Bran..
BU
07/31Apple, Merck rise; Caterpillar, Expedia fall
AQ
07/31Merck to move COVID-19 treatment into large trials, sees sales recovering thi..
RE
07/31MERCK & CO., INC. : Results of Operations and Financial Condition, Financial Sta..
AQ
07/31MERCK : Announces Two US Regulatory Milestones for KEYTRUDA in Triple-Negative B..
AQ
07/31MERCK : Expects Nearly $2 Billion Covid-19 Revenue Impact in 2020
DJ
07/31MERCK : 2Q Profit Rises Despite Lower Revenue
DJ
07/31MERCK : ups outlook, turns profit during global vaccine hunt
AQ
07/31MERCK : 2Q Earnings Snapshot
AQ
07/31MERCK :  Merck Announces Second-Quarter 2020 Financial Results
BU
More news
News in other languages on MERCK & CO., INC.
08/05MERCK : & CO., INC. Management's Discussion and Analysis of Financial Condition ..
08/05MERCK : Animal Health Completes Acquisition of IdentiGEN
08/04MERCK : accord de licence dans la maladie NASH
08/04MERCK : and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efino..
08/03MERCK : le titre dopé par un relèvement de recommandation
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Stock Trading Strategies
MERCK & CO., INC. - 08/03
Buyers are coming back
BUY
More Stock Trading Analysis
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Average target price 93,84 $
Last Close Price 81,05 $
Spread / Highest target 32,0%
Spread / Average Target 15,8%
Spread / Lowest Target -0,06%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-10.89%206 068
JOHNSON & JOHNSON0.93%390 711
ROCHE HOLDING AG1.04%299 337
PFIZER, INC.-1.86%213 583
NOVARTIS AG-17.36%184 831
ABBVIE INC.5.32%164 571